Anthera Pharmaceuticals: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
Anthera Pharmaceuticals | [[File:Anthera_Pharmaceuticals_logo.jpg|thumb]]==Anthera Pharmaceuticals== | ||
{{ | |||
Anthera Pharmaceuticals was a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, autoimmune disorders, and other unmet medical needs. The company was founded in 2004 and was headquartered in Hayward, California. | |||
===History=== | |||
Anthera Pharmaceuticals was established with the goal of developing innovative therapies for patients with unmet medical needs. The company initially focused on developing treatments for cardiovascular diseases and later expanded its pipeline to include therapies for autoimmune diseases and other inflammatory conditions. | |||
===Products and Pipeline=== | |||
Anthera Pharmaceuticals developed several investigational drugs, including: | |||
* '''[[Blisibimod]]''': A selective inhibitor of B-cell activating factor (BAFF), blisibimod was developed for the treatment of systemic lupus erythematosus (SLE) and IgA nephropathy. The drug aimed to reduce the activity of B-cells, which play a key role in autoimmune diseases. | |||
* '''[[Sollpura]]''': An investigational pancreatic enzyme replacement therapy for patients with exocrine pancreatic insufficiency (EPI) due to cystic fibrosis and other conditions. Sollpura was designed to improve fat absorption and nutritional status in affected patients. | |||
===Clinical Trials=== | |||
Anthera Pharmaceuticals conducted multiple clinical trials to evaluate the safety and efficacy of its investigational drugs. The company faced challenges in achieving positive outcomes in some of its late-stage trials, which impacted its ability to bring products to market. | |||
===Challenges and Closure=== | |||
Despite its efforts to develop new therapies, Anthera Pharmaceuticals faced significant challenges, including clinical trial setbacks and financial difficulties. These challenges ultimately led to the company's decision to cease operations and liquidate its assets. | |||
==Related Pages== | |||
* [[Biopharmaceutical]] | |||
* [[Systemic lupus erythematosus]] | |||
* [[IgA nephropathy]] | |||
* [[Exocrine pancreatic insufficiency]] | |||
* [[Cystic fibrosis]] | |||
{{Pharmaceutical company}} | |||
[[Category:Defunct pharmaceutical companies of the United States]] | |||
[[Category:Companies based in Hayward, California]] | |||
[[Category:Biotechnology companies established in 2004]] | |||
Revision as of 04:20, 9 January 2025
==Anthera Pharmaceuticals==
Anthera Pharmaceuticals was a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, autoimmune disorders, and other unmet medical needs. The company was founded in 2004 and was headquartered in Hayward, California.
History
Anthera Pharmaceuticals was established with the goal of developing innovative therapies for patients with unmet medical needs. The company initially focused on developing treatments for cardiovascular diseases and later expanded its pipeline to include therapies for autoimmune diseases and other inflammatory conditions.
Products and Pipeline
Anthera Pharmaceuticals developed several investigational drugs, including:
- Blisibimod: A selective inhibitor of B-cell activating factor (BAFF), blisibimod was developed for the treatment of systemic lupus erythematosus (SLE) and IgA nephropathy. The drug aimed to reduce the activity of B-cells, which play a key role in autoimmune diseases.
- Sollpura: An investigational pancreatic enzyme replacement therapy for patients with exocrine pancreatic insufficiency (EPI) due to cystic fibrosis and other conditions. Sollpura was designed to improve fat absorption and nutritional status in affected patients.
Clinical Trials
Anthera Pharmaceuticals conducted multiple clinical trials to evaluate the safety and efficacy of its investigational drugs. The company faced challenges in achieving positive outcomes in some of its late-stage trials, which impacted its ability to bring products to market.
Challenges and Closure
Despite its efforts to develop new therapies, Anthera Pharmaceuticals faced significant challenges, including clinical trial setbacks and financial difficulties. These challenges ultimately led to the company's decision to cease operations and liquidate its assets.
